The Gamaleya Research Institute has begun preclinical research on a platform for vaccines that can further protect against several different viruses or several variants of the same virus. This was reported to TASS by the director of the center Alexander Gintsburg.
Ðîññèÿ. Ìîñêâà. Ñîòðóäíèê Íàöèîíàëüíîãî èññëåäîâàòåëüñêîãî öåíòðà ýïèäåìèîëîãèè è ìèêðîáèîëîãèè èì. Ãàìàëåè Ìèíçäðàâà Ðîññèè âî âðåìÿ ïðåçåíòàöèè àâòîìàòè÷åñêîãî êîìïëåêñà ïî äåòåêöèè áèîïàòîãåíîâ. Ìèõàèë Ìåòöåëü/ÒÀÑÑ
“This is a vaccine that we have now begun to test in preclinical trials on monkeys. The idea of this technology is that <…> it is possible to immediately protect [a person] from different strains of the same pathogen or even from different viruses circulating in the human population at the same time <…>. Such an approach is possible – [combine] different antigens of influenza and coronavirus viruses”, he said.
Earlier, the Mash edition, citing Doctor of Biological Sciences Alexei Granovsky, reported that the Center. Gamalei is testing an additive that enhances the effect of the Sputnik V vaccine on monkeys. Gunzburg denied this information, explaining that it is about testing a new platform, and Sputnik V is already effective against existing strains of coronavirus.
“This technology has nothing to do with Sputnik V, except that both were developed at the Gamaleya Institute,” he concluded.